RCT | Deucravacitinib vs. placebo vs. apremilast in moderate to severe plaque psoriasis.
15 Jul, 2022 | 12:26h | UTCDeucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial – Journal of the American Academy of Dermatology (link to abstract – $ for full-text)